PARIS – Nonalcoholic steatohepatitis (NASH), along with its forerunner conditions, and the constellation of viral hepatitis infections – A, B, C, D and, for some regions of the world, E – seemed to generate the most attention at the 2018 International Liver Congress (ILC), the annual meeting of the European Association for the Study of the Liver (EASL). However, rare liver indications garnered their share of the spotlight, included several presentations singled out by EASL for potentially high impact.